We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Mount Sinai Establishes Center for Cardiovascular Medical Devices

By HospiMedica International staff writers
Posted on 16 Jul 2014
Print article
Image: Dr. David Adams and Dr. Julie Swain of CMeD (Photo courtesy of Mount Sinai Heart).
Image: Dr. David Adams and Dr. Julie Swain of CMeD (Photo courtesy of Mount Sinai Heart).
Mount Sinai Heart (New York, NY, USA) has created an innovative Center for Medical Devices (CMeD) to advance the field of cardiovascular medicine and accelerate the delivery of promising medical devices to cardiac patients.

Located at the Icahn School of Medicine at Mount Sinai (New York, NY, USA), the CMeD will help further develop technologies and test medical devices in advanced clinical trials toward the strategic goal of regulatory approval, thus accelerating cardiac devices delivery to patients who need them. Services available through CMeD include cardiac medical device assessment and evaluation, regulatory approval strategies, advanced clinical trial design, data interpretation, assistance with FDA submissions, and potential access to clinical testing at Mount Sinai.

In addition, CMeD will be a training center for future medical professionals wishing to gain experience in advanced clinical trial design and evaluation of medical devices. To do so, Mount Sinai Heart has Recruited Julie Swain, MD, a practicing cardiothoracic surgeon for more than 25 years and clinical trials expert who has consulted for the US Food and Drug Administration (FDA). In addition to her role as Director of CMeD, Dr. Swain will serve as Professor of Cardiovascular Surgery and Director of Clinical Research in the Department of Cardiovascular Surgery at Mount Sinai.

“Our mission at CMeD will be to provide the critical expertise and guidance needed by medical device companies, inventors, and researchers to further develop and test innovative cardiac medical devices that show promise to advance the field of cardiovascular medicine and the heart health of patients around the globe,” said Dr. Swain. “If you need help at any stage of your promising cardiac medical device’s research and development, ranging from the earliest development of your medical device to the final regulatory FDA approval, our experienced team at CMeD at Mount Sinai Heart can help.”

“Dr. Swain is internationally acclaimed for her leadership as the key advisor on cardiac device trial design and data interpretation for the Food and Drug Administration over the past decade,” commented David Adams, MD, chairman of the department of cardiovascular surgery. “She has been at the center of every major cardiac device trial in this role, and is thus uniquely positioned to lead our medical device program going forward. I expect this program to be a national level resource that will bring us access to a number of cutting edge clinical research opportunities, and assure our position as a leader in this space.”

Mount Sinai Heart is ranked No. 13 for heart services by US News & World Report, and is home to the largest catheterization laboratory in the United States. Considered a world leader in all facets of cardiology care and research, it is also a world leader in mitral valve reconstruction.

Related Links:

Mount Sinai Heart
Icahn School of Medicine at Mount Sinai


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Instrument Table
Flexible and Rotatable 10-066
New
EBUS-TBNA Endoscope
BF-UC190F

Print article

Channels

Surgical Techniques

view channel
Image: Graphical abstract; Surgical field during endomyocardial biopsy and fluoroscopic images (Photo courtesy of Heart Rhythm, DOI: 10.1016/j.hrthm.2024.10.069)

Novel Method Combining Heart Biopsy and Device Implantation Reduces Complications Risk

Endomyocardial biopsy (EMB) is a crucial diagnostic tool for identifying various cardiac conditions; however, it carries a risk of complications due to its invasive nature. New research has introduced... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.